---
title: "Phio Pharmaceuticals Director Patricia A. Bradford acquires 6,500 common shares valued at $6,582.55"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/300161201.md"
description: "Phio Pharmaceuticals director Patricia A. Bradford purchased 6,500 common shares at $1.0127 each, totaling $6,582.55. Following this transaction, her direct beneficial ownership increased to 64,151 shares. The disclosure was filed via EDGAR on September 25, 2026."
datetime: "2026-09-25T20:02:26.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/300161201.md)
  - [en](https://longbridge.com/en/news/300161201.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/300161201.md)
generator: "portal-rs"
---

# Phio Pharmaceuticals Director Patricia A. Bradford acquires 6,500 common shares valued at $6,582.55

-   Phio Pharmaceuticals director Patricia A. Bradford reported a purchase of 6,500 common shares at USD 1.0127 each. \* Her direct beneficial ownership rose to 64,151 common shares following the transaction. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Phio Pharmaceuticals Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001683168-26-007432), on September 25, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [PHIO.US](https://longbridge.com/en/quote/PHIO.US.md)

## Related News & Research

- [Phio Pharmaceuticals Says PH-762 Is Well-Tolerated in Phase 1b Skin Cancer Trial](https://longbridge.com/en/news/304649838.md)
- [Phio Pharmaceuticals reports PH-762 is well tolerated in Phase 1b skin cancer trial](https://longbridge.com/en/news/304848915.md)
- [Phio Pharmaceuticals Announces e-Presentation at American Society for Dermatologic Surgery (ASDS) Annual Meeting | PHIO Stock News](https://longbridge.com/en/news/304851271.md)
- [Phio Pharmaceuticals Announces Invitation for Oral Presentation at 41st Annual SITC Meeting (Society for Immunotherapy of Cancer) | PHIO Stock News](https://longbridge.com/en/news/304651088.md)
- [Phio Pharmaceuticals Reports Q3 2026 Results and Business Update, Advances PH-762 Toward Phase 2b Initiation](https://longbridge.com/en/news/304765529.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**